A carregar...
2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results
BACKGROUND: Cabotegravir (CAB), an INI, is under development in both oral and long-acting (LA) injectable formulations. LATTE (NCT01641809) was designed to select a daily oral dose of CAB and evaluate a two-drug ART regimen with rilpivirine (RPV), as suppressive maintenance therapy. Results enabled...
Na minha lista:
| Publicado no: | Open Forum Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6809191/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz359.145 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|